Wave Life Sciences' WVE-007 Shows -14% Visceral Fat Reduction in Positive Phase 1 Data, Highlighting Muscle Preservation
Summary
Wave Life Sciences announced highly positive interim Phase 1 data for its investigational drug WVE-007, demonstrating significant and clinically meaningful improvements in body composition. A single dose led to a 14% placebo-adjusted reduction in visceral fat (p<0.05) and a 3% reduction in waist circumference, notably with muscle preservation (+2% lean mass) at six months. These results are particularly compelling as they were observed in participants with lower BMI than typically seen in later-stage obesity studies, and they differentiate WVE-007 from GLP-1 treatments by avoiding muscle loss. This strong early data significantly de-risks the program and suggests broad therapeutic potential beyond obesity, including MASH, type 2 diabetes, and cardiovascular disease. Investors will now watch for the initiation of the Phase 2a portion of the INLIGHT trial in Q2 2026, which is expected to further validate these findings in a higher BMI population.
At the time of this announcement, WVE was trading at $8.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $5.28 to $21.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.